XOLAIR (omalizumab)
MONOCLONAL ANTIBODIES TO IMMUNOGLOBULIN E (IGE) · CHRONIC IDIOPATHIC URTICARIA ·+4
GENENTECH
Drug class
Monoclonal Antibodies To Immunoglobulin E (IgE)
Monoclonal antibodies to immunoglobulin E (anti-IgE antibodies) are a class of targeted biologic agents designed to treat severe allergic and inflammatory disorders. Read more about Monoclonal Antibodies To Immunoglobulin E (IgE)
3 drugs in this class 2 manufacturers
Drugs in Monoclonal Antibodies To Immunoglobulin E (IgE)
XOLAIR (omalizumab)
MONOCLONAL ANTIBODIES TO IMMUNOGLOBULIN E (IGE) · CHRONIC IDIOPATHIC URTICARIA ·+4
GENENTECH
OMLYCLO (omalizumab-igec)
MONOCLONAL ANTIBODIES TO IMMUNOGLOBULIN E (IGE) · CHRONIC IDIOPATHIC URTICARIA ·+4
CELLTRION USA,
Filter & compare in the drug finder →
Opens the drug finder with Monoclonal Antibodies To Immunoglobulin E (IgE) preselected. Add indication or manufacturer filters there.
Monoclonal antibodies to immunoglobulin E (anti-IgE antibodies) are a class of targeted biologic agents designed to treat severe allergic and inflammatory disorders.
These agents selectively bind to free human circulating IgE, preventing its interaction with high-affinity IgE receptors on mast cells and basophils, which suppresses cell degranulation and the downstream cascade of inflammatory mediators.
Clinically exemplified by omalizumab, this drug class is primarily indicated for the management of moderate-to-severe persistent allergic asthma, chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps, and immunoglobulin E–mediated food allergies.
-
fda.gov
Monoclonal antibodies to immunoglobulin E (anti-IgE antibodies) are a class of targeted biologic agents designed to treat severe allergic and inflammatory disorders Clinically exemplified by omalizumab, this drug class is primarily indicated for the management of moderate-to-severe persistent allergic asthma, chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps, and immunoglobulin E–mediated food allergies
-
drugbank.com
Monoclonal antibodies to immunoglobulin E (anti-IgE antibodies) are a class of targeted biologic agents designed to treat severe allergic and inflammatory disorders These agents selectively bind to free human circulating IgE, preventing its interaction with high-affinity IgE receptors on mast cells and basophils, which suppresses cell degranulation and the downstream cascade of inflammatory mediators Clinically exemplified by omalizumab, this drug class is primarily indicated for the management ...
-
fda.gov
These agents selectively bind to free human circulating IgE, preventing its interaction with high-affinity IgE receptors on mast cells and basophils, which suppresses cell degranulation and the downstream cascade of inflammatory mediators
-
fda.gov
Clinically exemplified by omalizumab, this drug class is primarily indicated for the management of moderate-to-severe persistent allergic asthma, chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps, and immunoglobulin E–mediated food allergies
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.